WallStSmart

Insmed Inc (INSM)vsRevance Therapeutics, Inc. (RVNC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 136% more annual revenue ($606.42M vs $256.94M). INSM leads profitability with a -2.1% profit margin vs -71.8%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

RVNC

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

RVNC0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

RVNC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$381.02M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-21.0%2/10

ROE of -21.0% — below average capital efficiency

Free Cash FlowQuality
$-41.15M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : RVNC

Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : RVNC

The primary concerns for RVNC are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

RVNC is growing revenue faster at 10.7% — sustainability is the question.

RVNC generates stronger free cash flow (-41M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Revance Therapeutics, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.

Want to dig deeper into these stocks?